Factors affecting the adoption and use of gene expression profiling by oncologists in clinical practice

Dhaval Patil; Amalia M Issa

doi:10.2217/pme.14.62

Factors affecting the adoption and use of gene expression profiling by oncologists in clinical practice

Per Med. 2015 Jan;12(1):33-42. doi: 10.2217/pme.14.62.

Authors

Dhaval Patil¹, Amalia M Issa^{1

2}

Affiliations

¹ Program in Personalized Medicine & Targeted Therapeutics, University of the Sciences, Philadelphia, PA 19104, USA.
² Department of Health Policy & Public Health, University of the Sciences, Philadelphia, PA 19104, USA.

PMID: 29767541
DOI: 10.2217/pme.14.62

Abstract

Aim: In this study, we evaluated the association between oncologists' perceptions of and attitudes toward one frequently used gene expression profiling assays, the Oncotype DX^® and oncologists' intention to use this assay in making treatment recommendations for breast cancer patients.

Methods: A nationally representative sample of breast cancer oncologists was surveyed using an adapted technology acceptance model.

Results: The survey response rate was 44.1%. The test characteristics `validity of the test' (p = 0.006) and 'use of Oncotype DX by fellow oncologists' (p = 0.0068) were significantly associated with use of the assay by oncologists. Oncologists' intention to use Oncotype DX increased consistently with their perceptions about its usefulness (β = 0.222). Insurance status of the patients was also significantly associated with physicians' use of Oncotype DX (p = 0.008).

Conclusion: We report a novel application of an adapted technology acceptance model to understand the adoption of gene expression profiling by oncologists who treat breast cancer patients in making treatment recommendations.

Keywords: Oncotype DX®; breast cancer; gene expression profiling; molecular diagnostics; multigene predictors; personalized medicine; pharmacogenomics; physicians’ perceptions; technology acceptance model; utility; utilization factors.